NO20064277L - 6-substituerte 2,3,4,5-tetrahydro-1H-benzo[d]azepiner som 5-HT2C reseptoragonister - Google Patents

6-substituerte 2,3,4,5-tetrahydro-1H-benzo[d]azepiner som 5-HT2C reseptoragonister

Info

Publication number: NO20064277L
Authority: NO; Norway
Prior art keywords: azepines; benzo; tetrahydro; substituted; receptor agonists
Prior art date: 2004-02-25

Application number

NO20064277A

Other languages

English (en)

Norwegian (no)

Inventor

Michael John Rodriguez

Roger Ryan Rothhaar

Frantz Victor

Michael Philip Cohen

John Gordon Allen

Karin Briner

Christopher Stanley Galka

Sarah Lynne Hellman

Maria Angeles Martinez-Grau

Matthew Robert Reinhard

Michael Wade Tidwell

Andrew Caerwyn Williams

Devi Zhang

Steven Armen Boyd

Richard Gerard Conway

Arundhati S Deo

Wai-Man Lee

Christopher Stephen Siedem

Ajay Singh

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-25

Filing date

2006-09-21

Publication date

2006-11-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064277(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-09-21 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2006-11-22 Publication of NO20064277L publication Critical patent/NO20064277L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Addiction (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Anesthesiology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

NO20064277A 2004-02-25 2006-09-21 6-substituerte 2,3,4,5-tetrahydro-1H-benzo[d]azepiner som 5-HT2C reseptoragonister NO20064277L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US54768104P	2004-02-25	2004-02-25
PCT/US2005/005418 WO2005082859A1 (en)	2004-02-25	2005-02-18	6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists

Publications (1)

Publication Number	Publication Date
NO20064277L true NO20064277L (no)	2006-11-22

Family

ID=34910927

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20064277A NO20064277L (no)	2004-02-25	2006-09-21	6-substituerte 2,3,4,5-tetrahydro-1H-benzo[d]azepiner som 5-HT2C reseptoragonister

Country Status (29)

Country	Link
US (2)	US8022062B2 (zh)
EP (2)	EP1720836B1 (zh)
JP (1)	JP4796047B2 (zh)
KR (1)	KR100848411B1 (zh)
CN (3)	CN1934088A (zh)
AR (1)	AR048242A1 (zh)
AU (1)	AU2005217602B2 (zh)
BR (1)	BRPI0507986A (zh)
CA (1)	CA2556390C (zh)
CL (1)	CL2010001292A1 (zh)
CR (1)	CR8566A (zh)
DK (1)	DK1720836T3 (zh)
DO (1)	DOP2005000024A (zh)
EA (1)	EA011011B1 (zh)
EC (1)	ECSP066788A (zh)
ES (2)	ES2466641T3 (zh)
IL (1)	IL177267A (zh)
MA (1)	MA28486B1 (zh)
MY (1)	MY141992A (zh)
NO (1)	NO20064277L (zh)
NZ (2)	NZ549009A (zh)
PE (1)	PE20060010A1 (zh)
PL (1)	PL1720836T3 (zh)
PT (1)	PT1720836E (zh)
SI (1)	SI1720836T1 (zh)
SV (1)	SV2005002025A (zh)
UA (1)	UA85699C2 (zh)
WO (1)	WO2005082859A1 (zh)
ZA (1)	ZA200606580B (zh)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1632494A1 (en)	2004-08-24	2006-03-08	Ferring B.V.	Vasopressin v1a antagonists
ATE437859T1 (de) *	2005-09-01	2009-08-15	Lilly Co Eli	6-substituierte- 2,3,4,5-tetrahydro-1h- benzoädüazepine als 5-ht2c-rezeptoragonisten
PT1924561E (pt) *	2005-09-01	2013-01-16	Lilly Co Eli	Módulo de cabeça de impressão tendo uma fiada solta e controlador de impressora para lhe fornecer dados
JP5249031B2 (ja) *	2005-09-01	2013-07-31	イーライリリーアンドカンパニー	５−ＨＴ２Ｃ受容体アゴニストとしての６−Ｎ結合型へテロ環置換された２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン
CA2619566C (en) *	2005-09-01	2013-08-13	Eli Lilly And Company	6-substituted-2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
EP2727585A1 (en)	2006-05-16	2014-05-07	Takeda Pharmaceutical Company Limited	In-vivo screening method
US7897595B2 (en)	2006-05-26	2011-03-01	Forest Laboratories Holdings Limited	Pyridoazepine derivatives
AU2007283113A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2009063992A1 (ja)	2007-11-15	2009-05-22	Takeda Pharmaceutical Company Limited	縮合ピリジン誘導体およびその用途
WO2009111004A1 (en)	2008-03-04	2009-09-11	Arena Pharmaceuticals, Inc.	Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
EP2310372B1 (en)	2008-07-09	2012-05-23	Sanofi	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
CN101712675B (zh) *	2008-10-07	2013-07-03	江苏恒谊药业有限公司	苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用
EP2362765B1 (en) *	2008-12-01	2020-04-08	The Procter and Gamble Company	Perfume systems
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011012622A1 (en)	2009-07-30	2011-02-03	Glaxo Group Limited	Benzoxazinone derivatives for the treatment of glytl mediated disorders
JP2013503135A (ja)	2009-08-26	2013-01-31	サノフイ	新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
EP2504316A1 (en)	2009-11-23	2012-10-03	MSD Oss B.V.	Heterocylic compounds as antagonists of the orexin receptors
US20110269744A1 (en) *	2010-03-12	2011-11-03	Astellas Pharma Inc.	Benzazepine Compound
US9045431B2 (en)	2010-06-02	2015-06-02	Arena Pharmaceuticals, Inc.	Processes for the preparation of 5-HT2C receptor agonists
EP3485878A1 (en)	2010-09-01	2019-05-22	Arena Pharmaceuticals, Inc.	Modified-release dosage forms of 5-ht2c agonists useful for weight management
WO2012030953A1 (en)	2010-09-01	2012-03-08	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
US9365521B2 (en)	2010-09-01	2016-06-14	Arena Pharmaceuticals, Inc.	Non-hygroscopic salts of 5-HT2C agonists
AU2011296014A1 (en) *	2010-09-01	2013-04-04	Arena Pharmaceuticals, Inc.	Salts of lorcaserin with optically active acids
NZ608266A (en)	2010-09-01	2015-09-25	Arena Pharm Inc	Administration of lorcaserin to individuals with renal impairment
IN2013DN02552A (zh) *	2010-09-01	2015-08-07	Arena Pharm Inc
US9040525B2 (en)	2010-10-08	2015-05-26	Mochida Pharmaceutical Co., Ltd.	Cyclic amide derivative
EP2683700B1 (de)	2011-03-08	2015-02-18	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en)	2011-03-08	2014-08-19	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828995B2 (en)	2011-03-08	2014-09-09	Sanofi	Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de)	2011-03-08	2014-12-24	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2834465A1 (en)	2011-04-28	2012-11-01	Mochida Pharmaceutical Co., Ltd.	Cyclic amide derivative
WO2012152741A1 (de)	2011-05-10	2012-11-15	Bayer Intellectual Property Gmbh	Bicyclische (thio)carbonylamidine
CN103030604A (zh) *	2011-10-10	2013-04-10	上海医药工业研究院	4-烷基-5-甲酰基噻唑或5-甲酰基噻唑的制备方法
CN103145619A (zh) *	2012-06-15	2013-06-12	史慎德	7-氯-6-苯磺酰氨基-2,3,4,5-四氢-1H-苯并[d]氮杂*的制备
JP2015534563A (ja)	2012-10-09	2015-12-03	アリーナファーマシューティカルズ，インコーポレイテッド	体重管理の方法
HK1215170A1 (zh)	2012-11-14	2016-08-19	The Johns Hopkins University	治療精神分裂症的方法和組合物
EP2801575A1 (en)	2013-05-07	2014-11-12	Bayer CropScience AG	Heteroaryldihydropyridine derivatives as fungicides
WO2015066344A1 (en)	2013-11-01	2015-05-07	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists and compositions and methods of use
CN103864679B (zh) *	2014-03-21	2015-11-18	河南师范大学	一种3-甲基-2-吡啶甲酸甲酯的制备方法
CN104193656B (zh) *	2014-09-09	2016-01-06	太原理工大学	一种β-二羰基砜类化合物及其制备方法
CN105622511B (zh) *	2014-11-03	2018-01-23	北京瑞都医药科技有限公司	一种减肥药物及其制备方法
CN104496891A (zh) *	2014-12-06	2015-04-08	哈尔滨工业大学	吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法
CA2982824C (en)	2015-04-30	2023-11-21	Musc Foundation For Research Development	Oxindole compounds and pharmaceutical compositions thereof
EA034167B8 (ru)	2015-05-22	2021-04-27	Эйджинбайо, Инк.	Фармацевтические композиции леветирацетама пролонгированного высвобождения
CN110621669A (zh)	2017-05-04	2019-12-27	巴斯夫欧洲公司	防除植物病原性真菌的取代5-卤代烷基-5-羟基异噁唑类
US20210052600A1 (en)	2017-12-27	2021-02-25	Takeda Pharmaceutical Company Limited	Therapeutic agents for stress urinary incontinence and incotinence of feces
MX2021009163A (es)	2019-02-01	2021-09-10	Fmc Corp	Piridinas y pirimidinas sustituidas con diamino como herbicidas.
US20220227763A1 (en)	2019-05-29	2022-07-21	Syngenta Crop Protection Ag	Microbiocidal derivatives
CA3157848A1 (en)	2019-10-14	2021-04-22	The Regents Of The University Of California	Broad spectrum anti-cancer compounds
JP7693709B2 (ja) *	2020-04-26	2025-06-17	ジャンスー・エンファ・ファーマシューティカル・カンパニー・リミテッド	１，５－ジヒドロ－２，４－ベンゾジアゼピン－３－オン誘導体及びその使用
AR131541A1 (es)	2023-01-07	2025-04-09	Syngenta Crop Protection Ag	Compuestos de carboxamida novedosos
WO2025109114A1 (en)	2023-11-24	2025-05-30	Syngenta Crop Protection Ag	Novel carboxamide compounds
WO2025149637A1 (en)	2024-01-12	2025-07-17	Syngenta Crop Protection Ag	Novel carboxamide compounds
WO2025149629A1 (en)	2024-01-12	2025-07-17	Syngenta Crop Protection Ag	Novel carboxamide compounds
WO2026008750A1 (en)	2024-07-05	2026-01-08	Syngenta Crop Protection Ag	Novel carboxamide compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2265890A (en) *	1939-11-25	1941-12-09	Arrow Hart & Hegeman Electric	Combined face plate and receptacle
US4265890A (en) *	1978-07-07	1981-05-05	Smithkline Corporation	6-Phenyl thio- and 6-cyclohexyl thio-2,3,4,5-tetrahydro-1H-3-benzazepines
ZA792785B (en) *	1978-07-07	1980-08-27	Smithkline Corp	Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines
US4349472A (en)	1979-04-27	1982-09-14	Schering Corporation	(S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
EP0285287A3 (en) *	1987-03-23	1990-08-16	Smithkline Beecham Corporation	3-benzazepine compounds for use in treating gastrointestinal motility disorders
US4985352A (en)	1988-02-29	1991-01-15	The Trustees Of Columbia University In The City Of New York	DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
GB9116824D0 (en) *	1991-08-05	1991-09-18	Smithkline Beecham Corp	Chemical compounds
GB9119467D0 (en) *	1991-09-12	1991-10-23	Smithkline Beecham Corp	Chemical compounds
WO1995009159A1 (en)	1993-09-28	1995-04-06	Otsuka Pharmaceutical Company, Limited	Quinoxaline derivative as antidiabetic agent
US5698766A (en)	1995-04-05	1997-12-16	The Regents Of The University Of California	Transgenic animal model for testing drugs for treating eating disorders and epilepsy
EP1183238A1 (en)	1999-05-17	2002-03-06	Eli Lilly And Company	Metabotropic glutamate receptor antagonists
WO2001007416A1 (de)	1999-07-28	2001-02-01	Lonza Ag	Verfahren zur herstellung von pyridazincarbonsäurederivaten
CN1149212C (zh)	1999-09-29	2004-05-12	伊莱利利公司	用作再摄入抑制剂的哌啶衍生物
GB0005789D0 (en)	2000-03-11	2000-05-03	Knoll Ag	Therapeutic agents
EP1213017A3 (en)	2000-12-05	2003-11-12	Akzo Nobel N.V.	Use of a 5-HT2C receptor agonist for the treatment of hot flushes
JPWO2002074746A1 (ja) *	2001-03-16	2004-07-08	山之内製薬株式会社	ベンゾアゼピン誘導体
ES2250667T3 (es)	2001-07-13	2006-04-16	PHARMACIA & UPJOHN COMPANY LLC	Hexahidroazepino(4,5-g)indoles e indolinas como ligandos del receptor 5-ht.
BR0214529A (pt)	2001-11-28	2006-05-30	Upjohn Co	compostos terapêuticos
US6908939B2 (en)	2001-12-21	2005-06-21	Galderma Research & Development S.N.C.	Biaromatic ligand activators of PPARγ receptors
US6953787B2 (en)	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators

2005
- 2005-02-18 ES ES05723397.5T patent/ES2466641T3/es not_active Expired - Lifetime
- 2005-02-18 BR BRPI0507986-1A patent/BRPI0507986A/pt not_active IP Right Cessation
- 2005-02-18 US US10/598,302 patent/US8022062B2/en not_active Expired - Fee Related
- 2005-02-18 NZ NZ549009A patent/NZ549009A/xx not_active IP Right Cessation
- 2005-02-18 NZ NZ586553A patent/NZ586553A/en not_active IP Right Cessation
- 2005-02-18 CA CA2556390A patent/CA2556390C/en not_active Expired - Fee Related
- 2005-02-18 PL PL05723397T patent/PL1720836T3/pl unknown
- 2005-02-18 ES ES12161584.3T patent/ES2468741T3/es not_active Expired - Lifetime
- 2005-02-18 UA UAA200609265A patent/UA85699C2/ru unknown
- 2005-02-18 PT PT57233975T patent/PT1720836E/pt unknown
- 2005-02-18 EP EP05723397.5A patent/EP1720836B1/en not_active Expired - Lifetime
- 2005-02-18 CN CNA2005800057884A patent/CN1934088A/zh active Pending
- 2005-02-18 EP EP12161584.3A patent/EP2479168B1/en not_active Expired - Lifetime
- 2005-02-18 WO PCT/US2005/005418 patent/WO2005082859A1/en not_active Ceased
- 2005-02-18 JP JP2007500906A patent/JP4796047B2/ja not_active Expired - Fee Related
- 2005-02-18 SI SI200531852T patent/SI1720836T1/sl unknown
- 2005-02-18 CN CN2011101820767A patent/CN102311387A/zh active Pending
- 2005-02-18 AU AU2005217602A patent/AU2005217602B2/en not_active Ceased
- 2005-02-18 CN CN2011101821562A patent/CN102329267A/zh active Pending
- 2005-02-18 KR KR1020067019634A patent/KR100848411B1/ko not_active Expired - Fee Related
- 2005-02-18 EA EA200601546A patent/EA011011B1/ru not_active IP Right Cessation
- 2005-02-18 DK DK05723397.5T patent/DK1720836T3/da active
- 2005-02-23 DO DO2005000024A patent/DOP2005000024A/es unknown
- 2005-02-24 PE PE2005000219A patent/PE20060010A1/es not_active Application Discontinuation
- 2005-02-24 MY MYPI20050730A patent/MY141992A/en unknown
- 2005-02-24 AR ARP050100686A patent/AR048242A1/es not_active Application Discontinuation
- 2005-02-25 SV SV2005002025A patent/SV2005002025A/es unknown
2006
- 2006-08-03 IL IL177267A patent/IL177267A/en not_active IP Right Cessation
- 2006-08-07 ZA ZA200606580A patent/ZA200606580B/xx unknown
- 2006-08-23 CR CR8566A patent/CR8566A/es unknown
- 2006-08-24 EC EC2006006788A patent/ECSP066788A/es unknown
- 2006-09-21 NO NO20064277A patent/NO20064277L/no not_active Application Discontinuation
- 2006-09-25 MA MA29343A patent/MA28486B1/fr unknown
2010
- 2010-11-25 CL CL2010001292A patent/CL2010001292A1/es unknown
2011
- 2011-07-28 US US13/192,707 patent/US8580780B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CL2010001292A1 (es)	2011-07-15
EP2479168B1 (en)	2014-04-09
US8022062B2 (en)	2011-09-20
AR048242A1 (es)	2006-04-12
CA2556390C (en)	2012-10-02
AU2005217602A1 (en)	2005-09-09
EA200601546A1 (ru)	2007-02-27
AU2005217602B2 (en)	2011-02-17
US20120028961A1 (en)	2012-02-02
MA28486B1 (fr)	2007-03-01
PL1720836T3 (pl)	2014-09-30
KR20070001200A (ko)	2007-01-03
EP1720836A1 (en)	2006-11-15
IL177267A0 (en)	2006-12-10
NZ586553A (en)	2011-11-25
DK1720836T3 (da)	2014-05-05
EP1720836B1 (en)	2014-04-16
ES2468741T3 (es)	2014-06-16
US20090099155A1 (en)	2009-04-16
ECSP066788A (es)	2006-11-16
ZA200606580B (en)	2008-02-27
CN1934088A (zh)	2007-03-21
MY141992A (en)	2010-08-16
BRPI0507986A (pt)	2007-07-24
SV2005002025A (es)	2005-11-04
CR8566A (es)	2006-12-01
US8580780B2 (en)	2013-11-12
DOP2005000024A (es)	2005-11-15
PT1720836E (pt)	2014-07-16
KR100848411B1 (ko)	2008-07-28
SI1720836T1 (sl)	2014-06-30
EP2479168A1 (en)	2012-07-25
ES2466641T3 (es)	2014-06-10
JP4796047B2 (ja)	2011-10-19
WO2005082859A1 (en)	2005-09-09
CA2556390A1 (en)	2005-09-09
NZ549009A (en)	2010-08-27
CN102329267A (zh)	2012-01-25
UA85699C2 (en)	2009-02-25
JP2007523951A (ja)	2007-08-23
PE20060010A1 (es)	2006-02-11
IL177267A (en)	2011-10-31
EA011011B1 (ru)	2008-12-30
CN102311387A (zh)	2012-01-11

Publication	Publication Date	Title
NO20064277L (no)	2006-11-22	6-substituerte 2,3,4,5-tetrahydro-1H-benzo[d]azepiner som 5-HT2C reseptoragonister
CY1110531T1 (el)	2015-04-29	6-υποκατεστημενες-2,3,4,5-τετραϋδρο-1η-βενζο[d]αζεπινες ως αγωνιστες του υποδοχεα 5-ht2c
WO2007028083A3 (en)	2007-05-18	6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
TW200510324A (en)	2005-03-16	6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
CY1110486T1 (el)	2015-04-29	6-υποκατασταθεισες 2,3,4,5-τετραϋδρο-1η-βενζο[d]αζεπινες ως συναγωνιστες υποδοχεως 5-ηt2c
GB0504828D0 (en)	2005-04-13	Therapeutic agents
WO2007028132A3 (en)	2007-06-07	6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
TW200503705A (en)	2005-02-01	3-amino chroman and 2-amino tetralin derivatives
MXPA05013364A (es)	2006-03-17	Procedimiento para preparar 3-benzazepinas.
NO20076344L (no)	2008-02-27	Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren
DK1701951T3 (da)	2010-06-07	Modulatorer af perifere 5-HT receptorer
DE60213576D1 (de)	2006-09-14	ANTIDEPRESSIVE AZAHETEROCYCLYLMETHYL-DERIVATE VON 2,3-DIHYDRO-1,4-DIOXINOi2,3-föCHINOXALIN
IL190783A0 (en)	2008-11-03	Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders
GB0311349D0 (en)	2003-06-25	Therapeutic agents, compositions, preparations and uses
CY1113558T1 (el)	2016-06-22	6-αρυλαλκυλαμινο-2,3,4,5-τετραϋδρο-1η-βενζοδιαζεπινες ως αγωνιστες υποδοχεα 5-ht2c
CY1115160T1 (el)	2016-12-14	6-υποκατεστημενες 2,3,4,5-τετραϋδρο-1η-βενζο [d]αζεπινες ως αγωνιστες υποδοχεα 5-ht2c
DOP2004000972A (es)	2005-02-28	6-(2,2,2-trifluoroetilamino)-7-cloro-2,3,4,5-tetrahidro 1h-benzo[d] azepina como agonista del receptor 5-ht2c
NZ548743A (en)	2009-07-31	Novel indeno[2,1A]indenes and isoindol[2,1-A]indoles

Legal Events

Date	Code	Title	Description
2014-09-22	FC2A	Withdrawal, rejection or dismissal of laid open patent application